Andrx submits NDA for Lovastatin XL

ADRX submitted an NDA for its Lovastatin XL extended release tablet formulation of lovastatin, an HMG-CoA reductase inhibitor, to prevent vascular disease associated with dyslipidemia. ADRX expects to...